ArticleFrontiers in cellular and infection microbiology2026
Conformational plasticity and truncational effects on bovine lactoferricin: structural determinants of enhanced antimicrobial activity.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The rapid emergence of multidrug-resistant bacterial pathogens has created an urgent demand for alternative antimicrobial agents. Bovine lactoferricin (Lfcin B), a cationic antimicrobial peptide derived from bovine lactoferrin, exhibits potent broad-spectrum antibacterial activity. Although truncated derivatives of Lfcin B retain partial antimicrobial effects, their efficacy relative to full-length Lfcin B and the structural mechanisms governing their function remain poorly understood. Methods: Full-length Lfcin B and three truncated variants (Lfcin B15, Lfcin B9, and Lfcin B6) were synthesized using solid-phase peptide synthesis and characterized by RP-HPLC and MALDI-TOF-MS. Circular dichroism spectroscopy was employed to evaluate secondary structural changes under different ionic and hydrophobic environments. Tertiary structures were predicted using AlphaFold3. Antibacterial activities were assessed against multidrug-resistant Gram-negative and Gram-positive pathogens, including Results: Circular dichroism spectroscopy revealed that ionic strength and hydrophobic environments modulate the secondary structures of the peptides, with increased ionic strength consistently reducing random coil ratios across all variants. Structural stability progressively diminished with peptide truncation, as shorter variants exhibited less conformational complexity. AlphaFold3-predicted tertiary structures identified two distinct conformations for full-length Lfcin B, an α-helix-rich state and a β-sheet-dominant topology, whereas truncated variants adopted simpler structural ensembles, primarily α-helical or random coil conformations. Antibacterial activity decreased markedly with peptide truncation. Lfcin B demonstrated the strongest and broadest-spectrum antibacterial activity, showing substantially lower MIC and MBC values and larger inhibition zones than truncated peptides. In contrast, Lfcin B6 exhibited only limited activity against Conclusions: The antibacterial efficacy of bovine Lfcin B is strongly associated with its full-length sequence, conformational adaptability, and disulfide bond-mediated structural stability. Progressive truncation compromises structural plasticity and significantly attenuates antimicrobial activity. These findings support Lfcin B as a promising structural scaffold for the development of next-generation therapeutics against antibiotic-resistant bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.